ArticleAnnals of dermatology2021
Consensus Update for Systemic Treatment of Atopic Dermatitis.
Article in Annals of dermatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Emerging trends and research hotspots in atopic dermatitis-related itch over the past 10 years: a bibliometric and visual analysis.Frontiers in medicine · 2025Pooled it
- Vitamin D and Atopic Dermatitis-A Mere Correlation or a Real Supportive Treatment Option?Nutrients · 2025Review
- Consensus-Based Guidelines for the Treatment of Atopic Dermatitis in Korea (Part II): Biologics and JAK inhibitors.Annals of dermatology · 2025Article
- Allergen immunotherapy and dupilumab in atopic dermatitis: Clinical efficacy and disparities in immunological indicators.The World Allergy Organization journal · 2025Article
- Evaluating the Real-World Effectiveness of Systemic Treatments in Atopic Dermatitis Using the Atopic Dermatitis Control Tool (ADCT): A Multi-Centre, Prospective Study.Acta dermato-venereologica · 2025Observational
- Advanced Systemic Treatments in Patients with Moderate-to-Severe Atopic Dermatitis: Key Learnings from Physicians Practicing in Nine Asian Countries and Territories.Dermatology and therapy · 2024Article
- Management of Moderate-to-Severe Atopic Dermatitis in Adults: A Cross-Sectional Survey of Dermatologists Within the Asia-Pacific Region.Dermatology and therapy · 2024Article
- Delphi Consensus Statement on the Role of Probiotics in the Treatment of Atopic Dermatitis.Cureus · 2024Article
- Long-Term Use of Oral Corticosteroids and Safety Outcomes for Patients With Atopic Dermatitis.JAMA network open · 2024Article
- Population-based cohort study to investigate the changes in prevalence, severity profile, and treatment modalities used in Korean atopic dermatitis patients.Scientific reports · 2024Article
- Preliminary Clinical Study of the Effects and Safety of 308-nm Excimer Light Treatment in Patients with Atopic Dermatitis.Annals of dermatology · 2023Article
- Burden of Disease and Unmet Needs in the Diagnosis and Management of Atopic Dermatitis in Korea.Journal of clinical medicine · 2023Review
- Effect of Vitamin D on the Treatment of Atopic Dermatitis With Consideration of Heterogeneities: Meta-Analysis of Randomized Controlled Trials.Allergy, asthma & immunology research · 2023Article
- Current and Emerging Therapies in Pediatric Atopic Dermatitis.Dermatology and therapy · 2022Review
- Clinical Implication of Serum Adiponectin Levels in Adult Patients with Atopic Dermatitis.Journal of clinical medicine · 2022Article
- Real-world treatment patterns for atopic dermatitis in South Korea.Scientific reports · 2022Observational
- Use of Dexpanthenol for Atopic Dermatitis-Benefits and Recommendations Based on Current Evidence.Journal of clinical medicine · 2022Review
- Immunopathology and Immunotherapy of Inflammatory Skin Diseases.Immune network · 2022Review
- Once-Daily Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults and Adolescents Aged 12 Years and Over: A Short Review of Current Clinical Perspectives.Therapeutics and clinical risk management · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 15 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn 2015, the Korean Atopic Dermatitis Association (KADA) working group published consensus guidelines for treating atopic dermatitis (AD).
objectiveWe aimed to provide updated consensus recommendations for systemic treatment of AD in South Korea based on recent evidence and experience.
methodsWe compiled a database of references from relevant systematic reviews and guidelines on the systemic management of AD. Evidence for each statement was graded and classified based on thestrength of the recommendation. Forty-two council members from the KADA participated in three rounds of voting to establish a consensus on expert recommendations.
resultsWe do not recommend long-term treatment with systemic steroids forpatients with moderate-to-severe AD due to the risk of adverse effects. We recommend treatment with cyclosporine or dupilumab and selective treatment with methotrexate or azathioprine for patients with moderate-to-severe AD. We suggest treatment with antihistamines as an option for alleviating clinical symptoms of AD. We recommend selective treatment with narrowband ultraviolet B for patients with chronic moderate-to-severe AD. We do not recommend treatment with oral antibiotics for patients with moderate-to-severe AD but who have no signs of infection. We did not reach a consensus on recommendations for treatment with allergen-specific immunotherapy, probiotics, evening primrose oil, orvitamin D for patients with moderate-to-severe AD. We also recommend educational interventions and counselling for patients with AD and caregivers to improve the treatment success rate.
conclusionWe look forward to implementing a new and updated consensus of systemic therapy in controlling patients with moderate-to-severe AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.